{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:59:11Z","timestamp":1792000751772,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11358-x","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:49:22Z","timestamp":1737726562000},"page":"4043-4054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Discordance between prostate MRI and PSMA-PET\/CT: the next big challenge for primary prostate tumor assessment?"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-8369","authenticated-orcid":false,"given":"Sungmin","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius E.","family":"Mayerhoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent P.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebert A.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"11358_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Omer A, Harriss E et al (2020) Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the Prostate Imaging Reporting and Data System era: a systematic review and meta-analysis. Eur Urol 78:402\u2013414. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.048","journal-title":"Eur Urol"},{"key":"11358_CR2","doi-asserted-by":"publisher","first-page":"433.e1","DOI":"10.1016\/j.urolonc.2020.10.018","volume":"39","author":"R Schiavina","year":"2021","unstructured":"Schiavina R, Droghetti M, Novara G et al (2021) The role of multiparametric MRI in active surveillance for low-risk prostate cancer: the ROMAS randomized controlled trial. Urol Oncol 39:433.e1\u2013433.e7. https:\/\/doi.org\/10.1016\/j.urolonc.2020.10.018","journal-title":"Urol Oncol"},{"key":"11358_CR3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"11358_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"11358_CR5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Cornel E, Isra\u00ebl B et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75:570\u2013578. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.023","journal-title":"Eur Urol"},{"key":"11358_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"11358_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR et al (2021) Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol 7:1635\u20131642. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771","journal-title":"JAMA Oncol"},{"key":"11358_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N et al (2021) The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol 80:682\u2013689. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.002","journal-title":"Eur Urol"},{"key":"11358_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1200\/JCO.2024.42.4_suppl.287","volume":"42","author":"A Dhar","year":"2024","unstructured":"Dhar A, Cendejas-Gomez JJ, Castro Mendez L et al (2024) Detection and delineation of intraprostatic lesions (IPLs) using multiparametric magnetic resonance imaging (mpMRI) and prostate specific membrane antigen positron emission tomography (PSMA PET) for patients with prostate cancer: a systematic review and meta-analysis. J Clin Oncol 42:287. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.287","journal-title":"J Clin Oncol"},{"key":"11358_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT et al (2022) Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med 63:847\u2013854. https:\/\/doi.org\/10.2967\/jnumed.121.262398","journal-title":"J Nucl Med"},{"key":"11358_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bju.14858","volume":"126","author":"AA Kalapara","year":"2020","unstructured":"Kalapara AA, Nzenza T, Pan HYC et al (2020) Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography\/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int 126:83\u201390. https:\/\/doi.org\/10.1111\/bju.14858","journal-title":"BJU Int"},{"key":"11358_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bju.15883","volume":"131","author":"S Ong","year":"2023","unstructured":"Ong S, Chen K, Grummet J et al (2023) Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? BJU Int 131:20\u201331. https:\/\/doi.org\/10.1111\/bju.15883","journal-title":"BJU Int"},{"key":"11358_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","volume":"98","author":"CAF Lawton","year":"2017","unstructured":"Lawton CAF, Lin X, Hanks GE et al (2017) Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys 98:296\u2013303. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.02.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11358_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39:787\u2013796. https:\/\/doi.org\/10.1200\/JCO.20.02873","journal-title":"J Clin Oncol"},{"key":"11358_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.2016161124","volume":"283","author":"AB Rosenkrantz","year":"2017","unstructured":"Rosenkrantz AB, Babb JS, Taneja SS, Ream JM (2017) Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate cancer detection. Radiology 283:119\u2013129. https:\/\/doi.org\/10.1148\/radiol.2016161124","journal-title":"Radiology"},{"key":"11358_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2. Eur Urol 76:340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"11358_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","volume":"141","author":"AS Bettermann","year":"2019","unstructured":"Bettermann AS, Zamboglou C, Kiefer S et al (2019) [68Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard\u2014implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol 141:214\u2013219. https:\/\/doi.org\/10.1016\/j.radonc.2019.07.005","journal-title":"Radiother Oncol"},{"key":"11358_CR18","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.2967\/jnumed.121.262687","volume":"63","author":"J Yang","year":"2022","unstructured":"Yang J, Tang Y, Zhu Z et al (2022) 68Ga-PSMA PET\/CT SUVmax and its derivative in predicting clinical significance of prostate cancer or prostate cancer. J Nucl Med 63:3067","journal-title":"J Nucl Med"},{"key":"11358_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.euo.2018.01.002","volume":"1","author":"A Stabile","year":"2018","unstructured":"Stabile A, Dell\u2019Oglio P, De Cobelli F et al (2018) Association between Prostate Imaging Reporting and Data System (PI-RADS) score for the index lesion and multifocal, clinically significant prostate cancer. Eur Urol Oncol 1:29\u201336. https:\/\/doi.org\/10.1016\/j.euo.2018.01.002","journal-title":"Eur Urol Oncol"},{"key":"11358_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.urology.2016.11.017","volume":"102","author":"DJ Bryk","year":"2017","unstructured":"Bryk DJ, Llukani E, Taneja SS et al (2017) The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy. Urology 102:178\u2013182. https:\/\/doi.org\/10.1016\/j.urology.2016.11.017","journal-title":"Urology"},{"key":"11358_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","volume":"82","author":"WG Brisbane","year":"2022","unstructured":"Brisbane WG, Priester AM, Ballon J et al (2022) Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling. Eur Urol 82:303\u2013310. https:\/\/doi.org\/10.1016\/j.eururo.2022.01.008","journal-title":"Eur Urol"},{"key":"11358_CR22","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J et al (2022) The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med 63:1644\u20131650. https:\/\/doi.org\/10.2967\/jnumed.121.263448","journal-title":"J Nucl Med"},{"key":"11358_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2967\/jnumed.123.266164","volume":"65","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Counter W et al (2024) Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database. J Nucl Med 65:94\u201399. https:\/\/doi.org\/10.2967\/jnumed.123.266164","journal-title":"J Nucl Med"},{"key":"11358_CR24","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1097\/RLU.0000000000004646","volume":"48","author":"Y-F Wang","year":"2023","unstructured":"Wang Y-F, Lo C-Y, Chen L-Y et al (2023) Comparing the detection performance between multiparametric magnetic resonance imaging and prostate-specific membrane antigen PET\/CT in patients with localized prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 48:e321\u2013e331. https:\/\/doi.org\/10.1097\/RLU.0000000000004646","journal-title":"Clin Nucl Med"},{"key":"11358_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41391-018-0048-7","volume":"21","author":"I Berger","year":"2018","unstructured":"Berger I, Annabattula C, Lewis J et al (2018) 68Ga-PSMA PET\/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis 21:204\u2013211. https:\/\/doi.org\/10.1038\/s41391-018-0048-7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"11358_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/1754-9485.13382","volume":"66","author":"N Parathithasan","year":"2022","unstructured":"Parathithasan N, Perry E, Taubman K et al (2022) Combination of MRI prostate and 18F-DCFPyl PSMA PET\/CT detects all clinically significant prostate cancers in treatment-naive patients: an international multicentre retrospective study. J Med Imaging Radiat Oncol 66:927\u2013935. https:\/\/doi.org\/10.1111\/1754-9485.13382","journal-title":"J Med Imaging Radiat Oncol"},{"key":"11358_CR27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s00259-018-3954-y","volume":"45","author":"L Thomas","year":"2018","unstructured":"Thomas L, Kantz S, Hung A et al (2018) 68Ga-PSMA-PET\/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost. Eur J Nucl Med Mol Imaging 45:1170\u20131178. https:\/\/doi.org\/10.1007\/s00259-018-3954-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11358_CR28","doi-asserted-by":"publisher","first-page":"781.e17","DOI":"10.1016\/j.urolonc.2021.01.027","volume":"39","author":"WP Tan","year":"2021","unstructured":"Tan WP, Rastinehad AR, Klotz L et al (2021) Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: recommendations of an international Delphi consensus. Urol Oncol 39:781.e17\u2013781.e24. https:\/\/doi.org\/10.1016\/j.urolonc.2021.01.027","journal-title":"Urol Oncol"},{"key":"11358_CR29","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(12)70121-3","volume":"13","author":"HU Ahmed","year":"2012","unstructured":"Ahmed HU, Hindley RG, Dickinson L et al (2012) Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 13:622\u2013632. https:\/\/doi.org\/10.1016\/S1470-2045(12)70121-3","journal-title":"Lancet Oncol"},{"key":"11358_CR30","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","volume":"68","author":"HU Ahmed","year":"2015","unstructured":"Ahmed HU, Dickinson L, Charman S et al (2015) Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 68:927\u2013936. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.030","journal-title":"Eur Urol"},{"key":"11358_CR31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00259-021-05599-3","volume":"49","author":"DA Ferraro","year":"2022","unstructured":"Ferraro DA, Laudicella R, Zeimpekis K et al (2022) Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET\/CT-guided biopsy in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 49:1721\u20131730. https:\/\/doi.org\/10.1007\/s00259-021-05599-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11358_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1148\/radiol.14140524","volume":"275","author":"F Bratan","year":"2015","unstructured":"Bratan F, Melodelima C, Souchon R et al (2015) How accurate is multiparametric MR imaging in evaluation of prostate cancer volume? Radiology 275:144\u2013154. https:\/\/doi.org\/10.1148\/radiol.14140524","journal-title":"Radiology"},{"key":"11358_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s12149-021-01606-7","volume":"35","author":"S Scobioala","year":"2021","unstructured":"Scobioala S, Kittel C, Wolters H et al (2021) Diagnostic efficiency of hybrid imaging using PSMA ligands, PET\/CT, PET\/MRI and MRI in identifying malignant prostate lesions. Ann Nucl Med 35:628\u2013638. https:\/\/doi.org\/10.1007\/s12149-021-01606-7","journal-title":"Ann Nucl Med"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11358-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T15:41:49Z","timestamp":1749829309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11358-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["11358"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11358-x","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Sungmin Woo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: Marius E. Mayerhoefer received honoraria for lectures from Siemens, GE, and BM but unrelated to the current work. Kent P. Friedman is a co-investigator on \u201cOptimizing timing of rhPSMA-7.3 (18F), for assessing site(s) of recurrent disease following radical prostatectomy\u201d (PI Herbert Lepor) but does not receive any salary support and is unrelated to the current work. David R. Wise has received consulting fees from Leap Therapeutics, Foundation Medicine, Pfizer, Janssen, Sanofi, Lilly, Labcorp, Myovant, Bayer, AstraZeneca, Accutar and has received travel funding from Pfizer and Bayer but unrelated to the current work. The other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required for this study because of the retrospective design and was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No overlap with prior studies.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}